Basilea Pharmaceutica

Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal

Retrieved on: 
Monday, November 13, 2023
NDA, Isavuconazonium, Pfizer, Safety, Food, US Foods, Basilea Pharmaceutica, Patient, FDA, Fungal infection, USD, CHF, FY, Candida auris, Pharmaceutical industry, Fungemia, Allschwil

In addition, Basilea has acquired the rights to a preclinical antifungal compound.

Key Points: 
  • In addition, Basilea has acquired the rights to a preclinical antifungal compound.
  • Fosmanogepix is a potential first-in-class antifungal treatment candidate with a novel mechanism of action.
  • Basilea assumes all rights and obligations from previous agreements, comprising potential development, regulatory, and commercial milestone payments of up to USD 396 million, as well as tiered single-digit royalty payments.
  • Correspondingly, the BARDA reimbursements, as well as operating expenses, will be reduced by the amount of such application fee.

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer

Retrieved on: 
Tuesday, February 7, 2023
NYSE, Basilea Pharmaceutica, Patient, PFE, CHF, Pharmaceutical industry, EU, Isavuconazonium, Pfizer

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region and China exceeded the threshold triggering a sales milestone payment of USD 1.25 million.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region and China exceeded the threshold triggering a sales milestone payment of USD 1.25 million.
  • David Veitch, Basilea’s Chief Executive Officer, stated: “We are very pleased that Cresemba sales in Asia Pacific and China are growing fast, resulting in the achievement of the second sales milestone payment within eight months and underscoring the significant commercial potential of the brand in this region.
  • Cresemba is well on track to become a leading global brand for the treatment of patients with invasive mold infections.”
    The license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries) as well as countries in the Asia Pacific region and China.
  • Under the agreement, Basilea is eligible for additional regulatory and sales milestone payments of up to around CHF 580 million, in addition to receiving mid-teen royalties on sales.

Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen

Retrieved on: 
Monday, December 19, 2022
Basilea Pharmaceutica, Patient, USD, Pharmaceutical industry, SillaJen, Basel

Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the achievement of a transition milestone for the oncology asset BAL0891 to SillaJen, Inc., triggering a pre-defined milestone payment of USD 4 million to Basilea.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the achievement of a transition milestone for the oncology asset BAL0891 to SillaJen, Inc., triggering a pre-defined milestone payment of USD 4 million to Basilea.
  • We look forward to SillaJen starting patient recruitment soon.”
    Upon closing of the agreement with SillaJen in September 2022, Basilea announced upfront and near-term milestones of USD 14 million.
  • The USD 10 million upfront payment has already been received.
  • Since BAL0891 is an in-licensed asset, Basilea remains responsible for making milestone and royalty payments under the corresponding license agreement.

Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics

Retrieved on: 
Wednesday, November 2, 2022
RNA, Basilea Pharmaceutica, DNA, Infection, Inflammation, Achievement, Cancer, CHF, Research, Disease, Intention, Program, Isavuconazonium, Mycosis, Maintenance, Sale, RNA splicing, Technology, Protein, Therapy, SIX Swiss Exchange, Communication, Patient, CLK, Vaccine, Pharmaceutical industry, Basel

Under the terms of the agreement, Basilea will receive an upfront payment of CHF 1 million and potential near-term milestone payments of CHF 2 million.

Key Points: 
  • Under the terms of the agreement, Basilea will receive an upfront payment of CHF 1 million and potential near-term milestone payments of CHF 2 million.
  • Basilea is eligible to receive further payments of up to CHF 351 million upon the achievement of predefined development, regulatory and sales milestones.
  • In February of this year, Basilea announced its intention to focus on becoming a leading anti-infectives company and therefore to separate its oncology assets.
  • Basilea has already made significant progress in the implementation of the new strategy and expects no material expenses related to oncology activities beyond 2022.

Spero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer

Retrieved on: 
Thursday, September 15, 2022
Adult, American University, MPH, American University of Beirut, Roivant Sciences, Time, Joint Medical Service (Germany), American College, COVID-19, Infection, Risk, FDA, Urinary tract infection, U.S. Securities and Exchange Commission, Basilea Pharmaceutica, Degenerative disease, Partnership, CMO, Therapy, Medical Affairs Bureau, Program, Patient, University, MBA, Bristol Myers Squibb, Physician, American College of Physicians, Tebipenem, Nasdaq, Stanford University School of Medicine, Novartis, Internal medicine, Johns Hopkins University, Pyelonephritis, Research, GLOBE, HBR, Cutis verticis gyrata, Infectious Diseases Society of America, Robert Wood Johnson Medical School, Pharmaceutical industry, MD, Bayer, Aleksei Lysov, Spero

CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO).

Key Points: 
  • CAMBRIDGE, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc.(Nasdaq: SPRO) today announced the appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer (CMO).
  • Kamal joins Spero with an impressive track record of building and leading successful anti-infective franchises, said Ankit Mahadevia, MD, Chief Executive Officer of Spero Therapeutics.
  • I am thrilled to have Kamal on our management team and look forward to working together.
  • Dr. Hamed has over 20 years of experience leading various anti-infective clinical development programs in antibacterials, antivirals, antimalarials, and antifungals.

Basilea announces sale of preclinical oncology program to Nodus Oncology

Retrieved on: 
Thursday, September 8, 2022
AstraZeneca, Partnership, Basilea Pharmaceutica, Program, Research, Max Planck Society, Infection, Achievement, SIX Swiss Exchange, DDR, DNA, PARG, Daiichi Sankyo, Mycosis, Antibody, CHF, LDC, DNA repair, Intention, Communication, Merck Group, Glossary of entomology terms, Boehringer Ingelheim, Industry, Acquisition, Isavuconazonium, Patient, Apeiron, Pharmaceutical industry, Bayer, Basel

The structure of the transaction ensures that Basilea continues to participate in the long-term value creation potential of this exciting program.

Key Points: 
  • The structure of the transaction ensures that Basilea continues to participate in the long-term value creation potential of this exciting program.
  • We also continue our ongoing partnering discussions for BAL0891 and our second pre-clinical program, for which we aim to complete transactions before the end of 2022.
  • Ian Waddell, Chief Executive Officer of Nodus Oncology, said: Nodus acquisition of Basileas PARG inhibitor program demonstrates our ongoing commitment to developing, and bringing to patients, drugs addressing next generation DDR targets.
  • Founded by Cumulus Oncology, which contributes capital and oncology discovery and development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors.

Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center

Retrieved on: 
Wednesday, April 27, 2022
Pharmacology, Infection, Isavuconazonium, Achievement, Assistant Secretary of Defense for Health Affairs, PDDI, FCCDC, Research, Mycosis, Patient, SIX Swiss Exchange, Biomedical Research, PABC, Communication, Basilea Pharmaceutica, Assistant, Cancer, Defense, ADME, Pharmaceutical industry

Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: This agreement shows our commitment to implementing our new corporate strategy, with a future focus on anti-infectives.

Key Points: 
  • Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: This agreement shows our commitment to implementing our new corporate strategy, with a future focus on anti-infectives.
  • The profile and the broad antifungal activity of the lead compound shown in preclinical studies are very promising.
  • Under the terms of the agreement, Basilea is granted an exclusive worldwide license to FCCDCs antifungal program.
  • Fox Chase Chemical Diversity Center, Inc. (FCCDC) is based in Doylestown, Pennsylvania, USA, at the Pennsylvania Biotechnology Center (PABC) and is affiliated with the Pennsylvania Drug Discovery Institute (PDDI).

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Retrieved on: 
Wednesday, April 13, 2022
2009 Swiss Federal Council election, Board, Audit committee, Annual report, Infection, Isavuconazonium, COVID-19, Research, AGM, Mycosis, Proxy, Patient, SIX Swiss Exchange, Mission statement, Federal Council, Communication, Basilea Pharmaceutica, Delhi Sikh Gurdwara Management Committee, Article, Articles of association, Swiss, Professional Football Compensation Committee, Financial compensation, Cancer, Security (finance), Association, Director

Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at todays annual general meeting (AGM) for the financial year 2021.

Key Points: 
  • Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that shareholders approved all proposals of the board of directors at todays annual general meeting (AGM) for the financial year 2021.
  • In accordance with the COVID-19 Ordinance 3 issued by the Swiss Federal Council, the board of directors of Basilea Pharmaceutica Ltd. had decided to hold the AGM 2022 without the physical presence of shareholders.
  • At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the financial year 2021.
  • They also endorsed carrying forward the accumulated deficit and approved the discharge of the members of the Board of Directors and the Management Committee.

Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress

Retrieved on: 
Tuesday, March 8, 2022
Mycosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, European Society for Medical Oncology, Isavuconazonium, SIX Swiss Exchange, Research, MCI, Infection, Food, SAC, Breast cancer, Safety, Oncology, Cell division, Chromosome, Cancer, Mitosis, Communication, ESMO, Basilea Pharmaceutica, PLK1, TTK, IND, Human, Pharmaceutical industry, Basel

BAL0891 is a potential first-in-class mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division, leading to tumor cell death.

Key Points: 
  • BAL0891 is a potential first-in-class mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division, leading to tumor cell death.
  • The preclinical data presented at ESMO TAT 2022 have been generated in collaboration with the Dutch precision medicine company, NTRC, from which Basilea in-licensed the drug candidate.
  • Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: We are very pleased with the strong single agent anti-cancer activity observed in preclinical models.
  • More preclinical data, including in-vivo data on the anti-cancer activity of BAL0891 in additional models of human cancers are planned to be presented at upcoming scientific conferences.

Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium

Retrieved on: 
Monday, January 24, 2022
Survival, Isavuconazonium, Patient, Research, Human, Cell proliferation, FGFR, Mycosis, SIX Swiss Exchange, DCR, Acral lentiginous melanoma, FGFR2, Neoplasm, Fibroblast, Squamous cell carcinoma, Toxic leukoencephalopathy, Safety, Epithelium, Paclitaxel, Infection, Merck, Society, Roche, CSF1R, Cancer, FGFR1, Progression-free survival, Basilea Pharmaceutica, American Society of Clinical Oncology, PFS, Prognosis, ICCA, Merck & Co., Communication, ASCO, PD-L1, Breast, Maintenance, Stomatitis, Pharmaceutical industry, Vaccine, EU, Cholangiocarcinoma

Dr. Marc Engelhardt, Chief Medical Officer, said: The updated interim results in iCCA patients with FGFR2 mutations and amplifications remain encouraging and support the therapeutic relevance of derazantinib in this group of patients where there has been limited clinical evidence of successful treatment with other FGFR inhibitors.

Key Points: 
  • Dr. Marc Engelhardt, Chief Medical Officer, said: The updated interim results in iCCA patients with FGFR2 mutations and amplifications remain encouraging and support the therapeutic relevance of derazantinib in this group of patients where there has been limited clinical evidence of successful treatment with other FGFR inhibitors.
  • Derazantinib has demonstrated clinically meaningful efficacy across all types of FGFR2 genetic aberrations, which confirms the broad potential of derazantinib as a monotherapy for the treatment of iCCA patients.
  • Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: Interim results from the phase 2 study FIDES-01.
  • The first study, FIDES-01, is a phase 2 study in patients with inoperable or advanced iCCA.